Foley & Lardner LLP represented AXA IM Alts, a global leader in alternative investments with over $190 billion of assets under management, as the lead investor in the $26 million Series A financing round for Maternal Newborn Health Innovations (MNHI), a U.S.-based public benefit corporation established to reduce the substantial burden of maternal and newborn mortality worldwide.
Beginning in 2023, MNHI plans to commercialize a new medical device designed to reduce maternal and newborn deaths and complications resulting from prolonged or complicated second-stage labor during childbirth. As part of a Series A financing round, AXA IM Alts’ investment will directly support MNHI in continuing its crucial work to develop solutions that provide safer and preferred methods for childbirth globally. MNHI will utilize the capital provided by AXA IM Alts to pursue regulatory approvals and commence commercial activities.
This is the first investment made by the newly launched AXA IM Alts’ $500 million Global Health Care Private Equity strategy, which focuses on four areas of innovation – medical devices, (bio)pharmaceuticals, vaccines, and diagnostics – through investing in health care companies that are in late-clinical or early commercial stages. The strategy seeks to invest in companies that aim to deliver health care solutions at accessible price points for global markets, including high-volume markets, where demand for new products continues to benefit from rapid growth in health care spending and population growth.
The Foley team representing AXA IM Alts was led by Partner Julie-Anne Lutfi and included Associates Justin Lauria-Banta and Graham MacEwan.
